Marzano L A, Porcelli A, Biondi B, Lupoli G, Delrio P, Lombardi G, Zarrilli L
Department of Molecular and Clinical Endocrinology and Oncology, Endocrine Surgery, University Federico II of Naples, Italy.
J Surg Oncol. 1995 Jul;59(3):162-8. doi: 10.1002/jso.2930590306.
Between 1977 and 1990 we operated on 33 patients with medullary thyroid carcinoma. We performed total thyroidectomy in 31 patients and central node dissection and/or lateral modified node dissection in 21 patients (63.3%). Two patients underwent radiotherapy after subtotal resection and tracheostomy. No perioperative death occurred. Twenty-five patients were followed (mean follow-up, 63.8 months) and 8 others were unavailable for follow-up. Three patients (1 with multiple endocrine neoplasia type IIB, 2 sporadic with distant metastases) died of their disease at 12, 18 and 36 months after initial operation. Of the remaining 22 patients, 4 with stage II disease were normocalcitoninemic even with pentagastrin stimulation, following total thyroidectomy and bilateral modified neck dissection and central node dissection. Eighteen other patients continued to have elevated calcitonin levels postoperatively. Only 10 patients with known cervical metastatic disease were reoperated upon. We performed extensive node dissection in all. In addition we resected recurrent tumor from the thyroid bed in 4 patients. Despite these extensive reoperations no patient became normocalcitoninemic. At the completion of the study (December 1991), 22 of the 25 patients followed were alive: 4 patients with normal calcitonin levels, baseline and after pentagastrin stimulation, and 18 with persistent mildly elevated calcitonin levels but no other evidence of disease. Our experience supports a very aggressive surgical approach at the time of the first operation for patients with medullary thyroid carcinoma. A lesser operation usually resulted in residual medullary thyroid carcinoma in the neck. We demonstrate the difficulty of achieving a cure by reoperation once the tumor becomes demonstrable by localization studies.
1977年至1990年间,我们为33例甲状腺髓样癌患者实施了手术。31例患者接受了甲状腺全切术,21例患者(63.3%)接受了中央区淋巴结清扫和/或侧方改良淋巴结清扫。2例患者在次全切除和气管切开术后接受了放疗。无围手术期死亡病例。25例患者得到随访(平均随访63.8个月),另外8例患者无法进行随访。3例患者(1例患有IIB型多发性内分泌腺瘤病,2例散发性伴有远处转移)在初次手术后12个月、18个月和36个月死于该病。其余22例患者中,4例II期疾病患者在甲状腺全切、双侧改良颈部清扫和中央区淋巴结清扫后,即使经五肽胃泌素刺激,降钙素水平仍正常。另外18例患者术后降钙素水平持续升高。仅10例已知有颈部转移疾病的患者接受了再次手术。我们均进行了广泛的淋巴结清扫。此外,我们对4例患者的甲状腺床复发性肿瘤进行了切除。尽管进行了这些广泛的再次手术,但没有患者的降钙素水平恢复正常。在研究结束时(1991年12月),接受随访的25例患者中有22例存活:4例患者的降钙素水平在基线及五肽胃泌素刺激后均正常,18例患者的降钙素水平持续轻度升高,但无其他疾病证据。我们的经验支持对甲状腺髓样癌患者首次手术时采取非常积极的手术方法。较小的手术通常会导致颈部残留甲状腺髓样癌。我们证明,一旦肿瘤通过定位研究得以显示,再次手术治愈的难度很大。